Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia

C. Lane Anzalone, Philip R. Cohen, Razelle Kurzrock, Jorge E. Cortes

Research output: Contribution to journalArticle

Abstract

Background: Imatinib mesylate is a selective tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia. Ocular side effects of imatinib include periorbital edema, which may become so severe as to obstruct the visual field. Purpose: The purpose of this case study is to describe the clinical characteristics of imatinib- induced postoperative periorbital purpura. Materials and methods: We retrospectively reviewed the medical literature using PubMed, searching the terms edema, Gleevec, imatinib, periorbital, postoperative and purpura. Patient reports and previous reviews of the subject were critically assessed and the salient features are presented. Results: Three patients have undergone surgery to reduce the imatinib-induced periorbital edema; two of these individuals have developed imatinib-induced postoperative periorbital purpura. Conclusion: We recommend discontinuing imatinib usage one week prior to periorbital surgery and not resuming therapy until the eighth postoperative day.

Original languageEnglish (US)
JournalDermatology Online Journal
Volume20
Issue number1
StatePublished - Jan 27 2014
Externally publishedYes

Fingerprint

Purpura
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Edema
Imatinib Mesylate
Visual Fields
PubMed
Protein-Tyrosine Kinases
Therapeutics

Keywords

  • Edema
  • Gleevec
  • Imatinib
  • Periorbital
  • Postoperative
  • Purpura

ASJC Scopus subject areas

  • Dermatology

Cite this

Imatinib-induced postoperative periorbital purpura : GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. / Anzalone, C. Lane; Cohen, Philip R.; Kurzrock, Razelle; Cortes, Jorge E.

In: Dermatology Online Journal, Vol. 20, No. 1, 27.01.2014.

Research output: Contribution to journalArticle

@article{18b8834c2a8242ac94f2624d4fe9392c,
title = "Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia",
abstract = "Background: Imatinib mesylate is a selective tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia. Ocular side effects of imatinib include periorbital edema, which may become so severe as to obstruct the visual field. Purpose: The purpose of this case study is to describe the clinical characteristics of imatinib- induced postoperative periorbital purpura. Materials and methods: We retrospectively reviewed the medical literature using PubMed, searching the terms edema, Gleevec, imatinib, periorbital, postoperative and purpura. Patient reports and previous reviews of the subject were critically assessed and the salient features are presented. Results: Three patients have undergone surgery to reduce the imatinib-induced periorbital edema; two of these individuals have developed imatinib-induced postoperative periorbital purpura. Conclusion: We recommend discontinuing imatinib usage one week prior to periorbital surgery and not resuming therapy until the eighth postoperative day.",
keywords = "Edema, Gleevec, Imatinib, Periorbital, Postoperative, Purpura",
author = "Anzalone, {C. Lane} and Cohen, {Philip R.} and Razelle Kurzrock and Cortes, {Jorge E.}",
year = "2014",
month = "1",
day = "27",
language = "English (US)",
volume = "20",
journal = "Dermatology Online Journal",
issn = "1087-2108",
publisher = "Department of Dermatology UC Davis",
number = "1",

}

TY - JOUR

T1 - Imatinib-induced postoperative periorbital purpura

T2 - GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia

AU - Anzalone, C. Lane

AU - Cohen, Philip R.

AU - Kurzrock, Razelle

AU - Cortes, Jorge E.

PY - 2014/1/27

Y1 - 2014/1/27

N2 - Background: Imatinib mesylate is a selective tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia. Ocular side effects of imatinib include periorbital edema, which may become so severe as to obstruct the visual field. Purpose: The purpose of this case study is to describe the clinical characteristics of imatinib- induced postoperative periorbital purpura. Materials and methods: We retrospectively reviewed the medical literature using PubMed, searching the terms edema, Gleevec, imatinib, periorbital, postoperative and purpura. Patient reports and previous reviews of the subject were critically assessed and the salient features are presented. Results: Three patients have undergone surgery to reduce the imatinib-induced periorbital edema; two of these individuals have developed imatinib-induced postoperative periorbital purpura. Conclusion: We recommend discontinuing imatinib usage one week prior to periorbital surgery and not resuming therapy until the eighth postoperative day.

AB - Background: Imatinib mesylate is a selective tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia. Ocular side effects of imatinib include periorbital edema, which may become so severe as to obstruct the visual field. Purpose: The purpose of this case study is to describe the clinical characteristics of imatinib- induced postoperative periorbital purpura. Materials and methods: We retrospectively reviewed the medical literature using PubMed, searching the terms edema, Gleevec, imatinib, periorbital, postoperative and purpura. Patient reports and previous reviews of the subject were critically assessed and the salient features are presented. Results: Three patients have undergone surgery to reduce the imatinib-induced periorbital edema; two of these individuals have developed imatinib-induced postoperative periorbital purpura. Conclusion: We recommend discontinuing imatinib usage one week prior to periorbital surgery and not resuming therapy until the eighth postoperative day.

KW - Edema

KW - Gleevec

KW - Imatinib

KW - Periorbital

KW - Postoperative

KW - Purpura

UR - http://www.scopus.com/inward/record.url?scp=84892704051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892704051&partnerID=8YFLogxK

M3 - Article

C2 - 24456946

AN - SCOPUS:84892704051

VL - 20

JO - Dermatology Online Journal

JF - Dermatology Online Journal

SN - 1087-2108

IS - 1

ER -